Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

GP block (Y3) > Week 9: Asthma and COPD > Flashcards

Week 9: Asthma and COPD Flashcards

1
Q

asthma

A

Asthma is a chronic respiratory condition associated with airway inflammation and hyper responsiveness causing reversible obstruction of the airways. Acute asthma involves:

  • Bronchospasm (smooth muscle spasm narrowing airways).
  • Excessive production of secretions (plugging airways).
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

RF for asthma

A
  • Personal/familial history of atopy
  • Inner city environment
  • Obesity
  • Viral infections in early childhood
  • Smoking
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

protective factors for asthma

A
  • Vaginal birth
  • Increasing sibship
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

triggers for asthma

A

e.g. exercise, allergen, irritant exposure, change in weather and viral resp infection- cause an inflammatory cascade within the bronchial tree

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

presentation of asthma

A
  • Wheeze, shortness of breath, chest tightness, cough
    • Symptoms worse at night and in early morning
    • Symptoms present in response to exercise, allergen exposure and cold air
    • Symptoms present after taking aspirin or beta-blockers or NSAIDs(ask about new drugs)
  • History of atopy e.g. eczema and hay fever
  • Low FEV volume (FEV:FVC ratio <70%)
  • Aggravating factors for attack
    • Cold symptoms I.e. UTRI
    • Cold air
    • Exercise
    • Cig smoke/ pollution
    • Allergens
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

diagnosis of asthma

A

clinical assessment

diagnostic test

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

clinical assessment in the diagnosis of asthma

A
  • History of recurrent episodes (attacks) of symptoms, ideally corroborated by variable peak flow when symptomatic and asymptomatic.
  • Symptoms of wheeze, cough, breathlessness and chest tightness that vary over time.
  • Recorded observation of wheeze heard by a healthcare professional.
  • Personal/family history of other atopic conditions (particularly atopic eczema/dermatitis, allergic rhinitis).
  • No symptoms/signs to suggest alternative diagnoses.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

diagnostic tests

A

should be done when patient is asymptomatic vs symptoms

e. g. peak flow
e. g. spirometry
e. g. FeNO
e. g. CXR

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

diagnosing children under 5 with asthma

A

Children under five or those unable to perform objective tests- use clinical judgement based on positive objective test results and presentation to determine likelihood of asthma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

DD for asthma

A
  • Bronchiolitis à in very young children
  • GORD- can cause cough on lying down
  • inhalation of foreign object
  • Croup (inspiratory stridor)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

complications of asthma

A
  • Pneumonia
  • Pneumothorax
  • Resp failure and arrest à see medicine block management
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

ollow up for asthma

A

annually and risk of asthma attack assessed

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

FVC

A

The volume breathed out during the forced expiration.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

FEV1

A

The volume breathed out during the first second

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

FEV1/FVC

A

The proportion of the FVC that is breathed out in the first second

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

PEFR

A

The Peak Expiratory Flow Rate – the gradient of the graph at time 0, which corresponds to the highest rate of flow of air from the lungs.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

spirometry

A
  • Preferred over Peak flow- can be used for initial confirmation of asthma
  • Calculates FVC and FEV1
  • Can also confirm reversibility in subjects with pre-existing obstruction of airway (after use of bronchodilator)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

eak flow

A
  • Measures peak expiratory flow rate
  • Simplest test
  • Important role in management of established asthma

interpretation

  • Patients peak flow can be compared with listed normal for their age, sex and height
  • Patients record peak flow diary – can provide objective warning of clinical deterioration
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

peak flow technique

A
  • Advise the patient to take in a deep breath and expel it as rapidly and as forcefully as possible into the meter.
  • The very first part is all that matters for this test and it is not necessary to empty the lungs completely.
  • Record the best of three tests. Continue blows if the two largest are not within 40 L/minute, as the patient is still acquiring the technique.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

FeNO

A
  • Measure amount of nitric oxide in breath
  • Increased levels related to lung inflammation and asthma
  • affected by smoking and inhaled corticosteroids
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

CXR

A
  • Normally normal even in severe asthma
  • Not used routinely in assessment of asthma
  • Could be used with atypical history/exam
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

4 principles of asthma management

A
  • Control symptoms
  • Prevent exacerbation
  • Achieve best possible lung functions
  • Minimise side effects
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

stepwise approach to asthma

A
  • Step 1 (mild, intermittent asthma)
    • Salbutamol (Beta 2-agonist)
    • Everyone offered and should be used PRN
  • Step 2 (if use of salbutamol more than 3 times a week, symptoms more than 3 times a week, waking due to asthma more than once a week)
    • Inhaled corticosteroid
  • Step 3 (if Beta-2 agonist/ inhaled steroid not enough)
    • Add on:
    • Leukotriene receptor antagonist (LTRA) before treatment with a long acting beta 2 agonist (LABA)
    • LABA should never be used without concurrent use of inhaled steroid
  • Step 4 (persistent poor control)
    • Add beclomethasone
    • And/or theophylline or beta2-agonsit tablet
  • Step 5
    • Continuous or frequent use of oral steroids, maintaining high dose inhaled steroids
  • (Referral to resp doctor at step 4-5)
  • Omalizumab- option for treating severe persistent allergic IgE mediated asthma
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

first step in treating asthma

A

get on SABA e.g. salbutamol

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

step 2 in asthma mangement

A

low dose ICS

e.g. prednisolone

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

step 3 in asthma management

A

add LTRA e.g. Montelukast or LABA e.g. salmeterol depending on guidelines

27
Q

step 4 in athma management

A

increase ICS to medium dose e.g. beclamethasone

add LTRA

stop LABA if no response

28
Q

step 5 asthma management

A

specialist

29
Q

LABA - what to remember

A

always prescribe with corticosteroid

30
Q

asthma management key points

A
  • Achieve early control
  • Step up or down medication to enable optimum control
  • Lowest dose of inhale steroid possible
  • Check compliance e.g. taking medication and inhaler technique
31
Q

normal spirometry finding

A

a normal FEV1, FVC and FEV1/FVC ratio.

32
Q

restrictive spirometry

A

a reduced FVC but with a normal FEV1/FVC ratio. [The FEV1 is reduced in proportion to the FVC]

e.g. pulmonary fibrosis

33
Q

obstructive spirometry

A

a normal FVC but with a reduced FEV1 and hence FEV1/FVC ratio. In obstruction, the PEFR is also reduced

<70%

34
Q

spirometry and reversibility

A

Bronchodilator reversibility typically involves repeating spirometry testing 20 – 30 mins after administering a dose of bronchodilator (typically Salbutamol 2 x 200mcg puffs, ideally via a large volume spacer). If there is ‘reversible’ airways obstruction, there will be an improvement in the FEV1/FVC ratio.

35
Q

types of inhalers

A

MDI- pressurised metered dose inhalers

DPIs- dry powder inhalers

SMIs- soft mist inhalers

36
Q

inhaler technique

A

generates an ‘aerosol’ which is inhaled.

  1. Test the inhaler- shake inhaler and press canister to release puff into air
  2. Now check that there is nothing inside the mouth piece and shake the inhaler well
  3. Sit or stand up straight and tilt your chin up
  4. Breathe out gently and slowly away from the inhaler until lungs feel empty
  5. Put lips around the mouthpiece to make a tight seal
  6. Start to breathe in slowly and steadily and at the same time press the canister on the inhaler once
  7. Continue to breathe in slowly until your lungs feel full
  8. Hold breathe for 10 seconds then breathe out gently away from your inhaler
  9. Repeat step 30-1 min later if required
  10. If inhaler contains steroids- rinse mouth with water
37
Q

Different drug groups of inhaler:

A
  1. SABA = Short Acting Beta Agonist
  2. LABA = Long Acting Beta Agonist
  3. SAMA = Short Acting Antimuscarinic (rarely used in asthma)
  4. LAMA = Long Acting Antimuscarinic (rarely used in asthma)
  5. ICS = Inhaled corticosteroids

Some inhalers contain single agents; some are combinations. Common combinations are:

  1. ICS/LABA (can be used in asthma and COPD)
  2. LABA/LAMA (mainly used in COPD)
  3. ICS/LABA/LAMA (mainly used in COPD)
38
Q

spacers

A

Spacers are useful devices which can improve inhaler technique. Several options are available.

39
Q

features of mild asthma

A

no features of severe asthma

PEFR >75%

40
Q

features of moderate asthma exacrbatuon

A

no features of severe

PEFR 50-75%

41
Q

features of severe asthma exacerbation

A

if any on of the following

  • PEFR 33-50% of best predicted
  • cannot complete sentences in 1 breath
  • RR >35/min
  • HR >110/min
42
Q

features of severe asthma exacerbation

A

if any one of the following

  • PEFR <33%
  • sat <92% of ABG pO2<9kPa
  • cyanosis, poor resp effort, silent chest
  • exhuastion, confusion, hypotension, arrhthmias
  • normal pCO2
43
Q

near fatal asthma exacerbation

A
  • rasised pCO2
44
Q

management of asthma exacerbation

A

Acute Asthma Management:

  • ABCDE
  • Aim for SpO2 94-98% with oxygen as needed, ABG if
  • sats <92%
  • 5mg nebulised Salbutamol (can repeat after 15 mins)
  • 40mg oral Prednisolone STAT (IV Hydrocortisone if
  • PO not possible)

If severe:

  • Nebulised Ipratropium Bromide 500 micrograms
  • Consider back-to-back Salbutamol

If life threatening or near fatal:

  • Urgent ITU or anaesthetist assessment
  • Urgent portable CXR
  • IV Aminophylline
  • Consider IV Salbutamol if nebulised route ineffective
45
Q

COPD

A
  • COPD is an umbrella term which encompasses emphysema and chronic bronchitis
  • Chronic obstructive pulmonary disease (COPD) is a common, treatable (but not curable) and largely preventable lung condition.
  • It is characterised by persistent respiratory symptoms (such as breathlessness, cough, and sputum) and airflow obstruction (usually progressive and not fully reversible).

Airflow obstruction results from chronic inflammation caused by exposure to noxious particles or gases (usually tobacco smoke but also from environmental and occupational exposures

46
Q

COPD pathophysiology

A
47
Q

COPD: Causes and risk factors

A
  • Smoking
  • Exposure to air pollution.
  • Breathing second hand smoke.
  • Working with chemicals, dust and fumes.
  • Alpha-1 deficiency.
  • Childhood respiratory infection.
48
Q

presentation of COPD

A
  • FEV1/FVC ratio is below <70% - non reversible with bronchodilators
  • Chronic cough w or without sputum
  • Shortness of breath during activity
  • Wheezing
  • Ankle oedema
    • Cor pulmonale
49
Q

diagnosis of COPD

A
  • Spirometry
  • CXR- can see bigger alveoli à air trapping à shows up as hyperdense
  • Hyperinflated chest, flat diaphragm
  • Severity of COPD is based on decreased FEV1
  • Can use MRC dyspnoea scale (symptomatic test)
  • Other tests
    • Alpha 1 antitrypsin level (genetic condition causing early onset COPD, even in people with no risk factors)
    • Investigations for heart disease (e.g. ECG, natriuretic peptide, echocardiogram)
    • Investigations for other lung disease (e.g. CT thorax, sputum culture)
    • Oxygen saturations (to check for hypoxia)
50
Q

empysema

A

Emphysema refers to a radiological/pathological change: “a condition of the lung characterized by abnormal, permanent enlargement of airspaces distal to the terminal bronchiole, accompanied by the destruction of their walls, and without obvious fibrosis”

  • Damage to walls of alveoli
  • Rather than lots of small alveoli, they breakdown forming larger alveoli à unable to support bronchioles
    • Bronchioles collapse and trap air inside the lungs
  • Changes in emphysema are irreversible
51
Q

causes of empysema

A
  • Smoking (must stop smoking to stop it getting worse)
  • Alpha 1- antitrypsin deficiency
52
Q

chronic bronchitits

A

Chronic bronchitis is the clinical term for cough and sputum production for at least 3 months in each of 2 consecutive years.

  1. Chronic inflammation of the bronchioles
  2. Inflammatory changes like asthma
  3. Instead of responding to allergen, it responds to irritants like cigarette smoke
    • Not T1 hypersensitivity
  4. Non-reversible
  5. Increased mucus and inflammation that causes narrowing of the airway → not bronchoconstriction
53
Q

management of COPD general

A
  • Smoking cessation advice e.g. nicotine replacement therapy
  • Vaccinations e.g. annual influenzas and pneumococcal
  • Pulmonary rehabilitation
  • pharmacological
    • inhaled treatment
    • prophylactic antibiotics
    • LTOT
  • mucolytics
54
Q

pulmonary rehab

A
  • Increase exercise tolerance
  • Anxiety management
  • Breathing technique
  • Teaching of how to clear chest of sputum
55
Q

inhaled treatment

A

Make sure patient has correct inhalation technique. Nebulised treatment should be considered for patients with distressing or disabling breathlessness

  • Initial treatment: SABA or SAMA
  • Step up treatment for patient without asthmatic features or features suggesting steroid responsiveness: LABA and a LAMA (discontinue SAMA if LAMA given)
    • SABA continued throughout all stages of treatment
    • Patients on LAMA and LABA who have severe exacerbations or at least 2 moderate exacerbations, consider addition of ICS INHALER (TRIPLE THERAPY)
  • Step up treatment for patient with asthmatic features or features suggesting steroid responsiveness
    • LABA and ICS
    • Patients on LABA and ICS who have severe exacerbations or at least 2 moderate exacerbations, consider addition of LAMA
56
Q

prophylactic antibiotics

A

azithromycin to reduce risk of exacerbation in patients who are non-smokers, have had all other treatment option optimised and have prolonged or frequent exacerbation with sputum production or resulting in hospitalisation- ensure sputum culture and sensitivity

57
Q

mucolytic treatment

A

carbocyteine

58
Q

Long Term Oxygen Therapy → oxygen reduction

A
  • Extended periods of hypoxia cause renal and cardiac damage – can be prevented by LTOT
  • LTOT to be used at least 16 hours/day for a survival benefit
  • LTOT offered if pO2 consistently below 7.3 kPa, or below 8 kPa with cor pulmonale
  • Patients must be non-smokers and not retain high levels of CO2
  • O2 needs should be balanced with loss of independence and reduced activity which may occur
  • Note: oxygen is not a treatment for breathlessness; it is a treatment to help prevent organ hypoxia
59
Q

contorlled oxyegn therapy

A
  • Stop CO2 retention
60
Q

Asthma-COPD overlap syndrome

A

NICE calls this “Asthmatic features/features suggesting steroid responsiveness”

This includes any previous, secure diagnosis of asthma or of atopy, a higher blood eosinophil count, substantial variation in FEV1 over time (at least 400 ml) or substantial diurnal variation in peak expiratory flow (at least 20%).

This might happen when:

  • A person has ‘confirmed’ asthma (i.e. has been investigated as recommended in topic 3) but continues to smoke (or is exposed to occupational risk factors)
  • A person has other atopic conditions and develops COPD.
  • A person with COPD is noted to have a raised eosinophil count.
61
Q

A person with COPD is noted to have a raised

A

eosinophil count

62
Q

COPD complications

A
  • Exacerbations of COPD
  • Cor pulmonale
  • Type 1 respiratory failure (‘hypoxic’ respiratory failure)
  • Type 2 respiratory failure (‘hypercapnic’ respiratory failure)
    • Blue bloaters
  • Secondary polycythaemia- chronic hypoxia
  • Anxiety and depression
63
Q

Cor pulmonale

A
  • right sided heart failure
  • due to pulmonary hypertension à hypoxia causes vasoconstriction of pulmonary BV
  • pulmonary hypertension results from hypoxia, inflammation, and loss of alveolar capillaries (related to emphysematous change).
  • increased pressure In the right ventricles due to pulmonary hypertension due to chronic hypoxiaà blood flow back to the RA reduced- ankle oedema
64
Q

blue bloater

A

Bronchitis

  • CO2 retention (insensitive to it
  • Type 2- hypercapnic resp failure

GP block (Y3) (39 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions